Company: INMB
Filing Date: 2025-10-30
Form Type: 10-Q
Source: 0001213900-25-104141
Chunk: 83

Company: Inmune Bio, Inc.
Filing Date: 2025-10-30
Form: 10-Q
Item: Part I, Item 2
Chunk 83
---
 been no material changes during the nine months ended September 30, 2025.

33

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Pursuant to Item 305(e) of
Regulation S-K (§ 229.305(e)), the Company is not required to provide the information required by this Item as it is a “smaller
reporting company,” as defined by Rule 229.10(f)(1). 

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our
management, with the participation of our Principal Executive Officer and Interim Chief Financial Officer, evaluated the effectiveness
of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended
(the “Exchange Act”)) at the end of the period covered by this Quarterly Report on Form 10-Q.

Based
on this evaluation, we concluded that, as of such date, our disclosure controls and procedures were effective to provide reasonable assurance
that the information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized
and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated
to management, including our Principal Executive Officer and Interim Chief Financial Officer, as appropriate to allow timely decisions
regarding required disclosure.

We
recognize that any controls system, no matter how well designed and operated, can provide only reasonable assurance of achieving its objectives,
and our management necessarily applies its judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Changes in Internal Control over Financial
Reporting

There
were no changes in our internal control over financial reporting during the period covered by this Quarterly Report on Form 10-Q that
materially affected, or are reasonably likely to materially affect, our internal control over financial reporting (as defined in Rules
13a-15(f) and 15d-15(f) under the Exchange Act).

34

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

We are not currently a party
to any pending legal proceedings that we believe will have a material adverse effect on our business or financial conditions. We may,
however, be subject to various claims and legal actions arising in the ordinary course of business from time to time.

Item 1A. Risk Factors

Not required for smaller reporting
companies.